Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor

Cho, Young and Liu, Gang and Caferro, Thomas and Shafer, Cynthia and Manning, James and Sendzik, Martin and Shultz, Michael and Chenail, Gregg and Dooley, Julie and Farsidjani, Alireza and Chen, Jinyun and Kulathila, Raviraj and Xie, Xiaoling and Dodd, Stephanie and Gould, Ty and Liang, Guiqing and Heimbach, Tycho and Slocum, Kelly and Pu, Minying and Pagliarini, Raymond and Growney, Joseph (2017) Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Medicinal Chemistry Letters, 8 (10). pp. 1116-1121. ISSN 19485875

Abstract

Inhibition of mutant IDH1 is being evaluated clinically as a promising treatment option for various cancers with hotspot mutation at Arg132. Having identified an allosteric, induced pocket of IDH1R132H, we have explored 3-pyrimidin-4-yl-oxazolidin-2-ones as mutant IDH1 inhibitors for in vivo modulation of 2-HG production and potential brain penetration. We report here optimization efforts toward the identification of clinical candidate IDH305 (13), a potent and selective mutant IDH1 inhibitor that has demonstrated brain exposure in rodents. Preclinical characterization of this compound exhibited in vivo correlation of 2-HG reduction and efficacy in a patient-derived IDH1 mutant xenograft tumor model. IDH305 (13) has progressed into human clinical trials for the treatment of cancers with IDH1 mutation.

Item Type: Article
Keywords: brain penetration clinical candidate in vivo anticancer activity inhibition of 2-HG production Mutant IDH1
Date Deposited: 17 Jan 2018 00:45
Last Modified: 25 Jan 2019 00:45
URI: https://oak.novartis.com/id/eprint/32520

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.